Search results for "recurrence"

showing 10 items of 1036 documents

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence

2012

<b><i>Background/Aims:</i></b> The molecular mechanisms downstream of mutated neurofibromatosis type 2 (NF2) gene resulting in the growth and development of vestibular schwannoma (VS) are controversial. Several lines of evidence suggest the involvement of the vascular endothelial growth factor (VEGF) pathway in VS development. Given that recent studies of VEGF blockade in patients with NF2-associated VS showed positive effects on VS growth control, we initiated this comprehensive study of the VEGF pathway in sporadic VS. <b><i>Methods:</i></b> A tissue microarray analysis of 182 sporadic VS was conducted. The expression of VEGF and its recepto…

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAdolescentYoung Adultchemistry.chemical_compoundNeuropilin 1medicineHumansNeurofibromatosis type 2ReceptorAgedCell ProliferationCell growthbusiness.industryNeuroma AcousticMiddle Agedmedicine.diseaseNeuromaImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Neuropilin-1BlockadeVascular endothelial growth factorReceptors Vascular Endothelial Growth FactorOtorhinolaryngologychemistryTissue Array AnalysisImmunohistochemistryFemaleNeoplasm Recurrence LocalbusinessORL
researchProduct

Immunohistochemical analysis of vascular endothelial growth factor (VEGF) and p53 expression in pterygium from Tunisian patients.

2009

A pterygium is characterized by abnormal fibrovascular corneoconjunctival tissue. A number of investigations have attempted to elucidate this incompletely understood pathology. Since vascular endothelial growth factor (VEGF) and p53 are known to participate in tumor vascularization, our purpose was to study VEGF and p53 expression in active primary and recurrent pterygium from Tunisian patients. To this end, 15 cases of active primary pterygium and five cases of recurrent pterygium from Tunisia were studied by immunohistochemistry. Antibodies raised against VEGF and p53 were used to analyze the distribution and expression of these markers in pterygium and normal human conjunctiva were used …

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyConjunctivaTunisiaAngiogenesisPterygiumPathogenesisNeovascularizationImmunoenzyme Techniqueschemistry.chemical_compoundYoung AdultRecurrenceMedicineHumansCorneal NeovascularizationAgedbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseGenes p53eye diseasesPathophysiologyPterygiumVascular endothelial growth factormedicine.anatomical_structurechemistryImmunohistochemistryFemalesense organsmedicine.symptomTumor Suppressor Protein p53businessConjunctivaPathologie-biologie
researchProduct

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial

2014

Purpose To compare standard-of-care grid laser photocoagulation versus intravitreal ranibizumab (IVR) versus a combination of both in the treatment of chronic (>3 months) macular oedema secondary to branch retinal vein occlusion. Methods Prospective, randomized, multicentre clinical trial. Thirty patients with a best-corrected visual acuity (BCVA) between 20/320 and 20/40 were randomized 1:1:1 to receive grid laser or three monthly injections of 0.5 mg IVR or both followed by 3 months of observation. Results Mean change from baseline BCVA at month 6 was +2 letters [laser; 0.04 logMAR, 95% confidence interval (−0.17; 0.25)], +17 letters [IVR; 0.34 (0.19; 0.5)] and +6 letters [combination; 0.…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular Edemalaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRecurrencelawRanibizumabOphthalmologyRetinal Vein OcclusionHumansMedicineProspective Studies030212 general & internal medicineMacular edemaAgedAged 80 and overLaser Coagulationbusiness.industryRetinalGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyConfidence interval3. Good healthSurgeryClinical trialOphthalmologychemistryIntravitreal Injections030221 ophthalmology & optometryBranch retinal vein occlusionFemaleLasers SemiconductorRanibizumabmedicine.symptombusinessmedicine.drugActa Ophthalmologica
researchProduct

Hereditary angioedema with normal C1-inhibitor activity in women.

2000

Summary Background Hereditary angioedema (HAE) is a well defined autosomal dominant disease (Mendelian Inheritance in Man #106100) that results from an inherited deficiency of C1 (the activated first component of complement) inhibitor function. We report an unusual variant of HAE with normal biochemical C1-inhibitor function, occurring only in women. Methods We screened 574 patients with recurrent angioedema of the skin for presence of HAE. 283 patients were selected, in whom angioedema was associated with abdominal pain attacks or recurrent life-threatening episodes of upper-airway obstruction, or both, rather than with urticaria. We measured C1-inhibitor concentration and functional activ…

AdultMaleX ChromosomeAdolescentGenetic LinkageComplement C1 Inactivator ProteinsC1-inhibitorEcallantideSex FactorsRecurrenceTerminology as TopicmedicineHumansHereditary Angioedema Type IIISex RatioFamily historyAngioedemaChildDominance (genetics)Genes DominantAngioedemabiologybusiness.industryAutosomal dominant traitComplement C4General MedicineMiddle Agedmedicine.diseaseAbdominal PainPedigreeAirway ObstructionImmunologyHereditary angioedemaMutationbiology.proteinFemalemedicine.symptombusinessmedicine.drugLancet (London, England)
researchProduct

Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life

2019

The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need.Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day. The primary endpoint was the objective response rate; secondary endpoints included quality of life (QOL) (according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items [EORTC QLQ-C30] and the European Organization for Research and Treatment of Cancer Quality of Life Question…

AdultMaleadenoid cystic carcinoma; lenvatinib; quality of life; toxicityCancer Researchmedicine.medical_specialtyAdenoid cystic carcinomaAntineoplastic Agentslenvatinib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSwallowingQuality of lifeInternal medicinemedicineClinical endpointHumansadenoid cystic carcinomaProspective Studies030212 general & internal medicineNeoplasm MetastasisProtein Kinase InhibitorsDose-Response Relationship Drugbusiness.industryPhenylurea CompoundstoxicityCancerCommon Terminology Criteria for Adverse EventsMiddle AgedSalivary Gland Neoplasmsmedicine.diseaseCarcinoma Adenoid CysticSurvival AnalysisSalivary Gland Adenoid Cystic Carcinomaquality of lifeOncologychemistry030220 oncology & carcinogenesisQuinolinesFemaleNeoplasm Recurrence LocalbusinessLenvatinibCancer
researchProduct

Food-additive-induced urticaria: a survey of 838 patients with recurrent chronic idiopathic urticaria

2005

<i>Background:</i> Recurrent chronic idiopathic urticaria (RCIU) is a common skin condition that affects 0.1–3% of the population in the USA and Europe and accounts for nearly 75% of all ‘ordinary’ chronic urticaria (CU) cases. <i>Methods:</i> We studied 838 consecutive patients with RCIU referred to hospital between 1998 and 2003. Patients with known causes of CU were excluded. Clinical history, physical examination, and symptom diaries were evaluated during two periods, a diet-free period (1 week) and a food-additive-free diet (FAFD) period (4 weeks), respectively, and two double-blind placebo-controlled (DBPC) challenges of six food additives were administered. Th…

AdultMalefood.ingredientSettore MED/09 - Medicina InternaAdolescentUrticariaImmunologyPopulationPlacebofoodDouble-Blind MethodRecurrenceImmunopathologyPrevalenceHumansImmunology and AllergyMedicinesurveyeducationFood-additive-induced urticariaAgededucation.field_of_studyrecurrent chronic idiopathic urticariaFood-additive-induced urticaria; survey; recurrent chronic idiopathic urticariabusiness.industryFood additiveGeneral MedicineMiddle AgedFood hypersensitivityChronic diseaseChronic DiseaseImmunologyFemaleFood AdditivesChronic idiopathic urticariabusinessFood Hypersensitivity
researchProduct

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of th…

2013

ObjectiveTo assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).MethodsPatients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.ResultsOf 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = …

AdultMalemedicine.medical_specialty5 year follow upMultiple SclerosisAdolescentScienceInjections SubcutaneousBrain damageYoung AdultInterferonRecurrenceInternal medicinemedicineHumansIn patientYoung adultCognitive impairmentSex CharacteristicsMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisQRMultiple Sclerosis Subcutaneous interferon β-1a cognitive impairmentMagnetic resonance imagingInterferon-betamedicine.diseaseTreatment OutcomeImmunologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptomSafetybusinessCognition DisordersInterferon beta-1amedicine.drugResearch ArticleFollow-Up Studies
researchProduct

2',5'-Oligoadenylate synthetase activity analysis and human papilloma virus typing as prognostic factors in patients with recurrent respiratory papil…

2004

Objective: Determination of early prognostic factors in patients with recurrent respiratory papillomatosis is extremely important, so the major goal of our prospective, multicentre study was to evaluate (1) the feasibility of various factors to determine prognosis of the clinical course,as well as (2) the response to interferon-alpha therapy in recurrent respiratory papillomatosis. Methods: Forty-two patients with recurrent respiratory papillomatosis were treated with interferon-alpha (3 MU/m2 three times per week; mean therapy duration was 2.7 ± 1.8 years)in 1983–1994 and followed-up until 2003. Human papilloma virus (HPV) type, recurrent respiratory papillomatosis severity and 2′,5′-oligo…

AdultMalemedicine.medical_specialtyAdolescent2'-5'-oligoadenylate synthetase activityAntineoplastic AgentsGastroenterologySeverity of Illness IndexVirusMalignant transformationBasal (phylogenetics)Internal medicinemedicine2'5'-Oligoadenylate SynthetaseHumansTypingProspective StudiesChildPapillomaviridaePapillomabusiness.industryInterferon-alphaGeneral Medicinemedicine.diseasePrognosisRespiratory Tract NeoplasmsTreatment OutcomeOtorhinolaryngologyChild PreschoolImmunologyDNA ViralLeukocytes MononuclearPapillomaFemaleRecurrent Respiratory PapillomatosisNeoplasm Recurrence LocalAirwaybusinessThe Journal of laryngology and otology
researchProduct

EPIDEMIOLOGICAL SURVEILLANCE OF VISCERAL LEISHMANIASIS IN SICILY, ITALY

1997

Abstract Visceral leishmaniasis (VL) is endemic in Sicily. Although it is a notifiable disease, there is evidence that the actual number of cases is higher than that reported. In 1987, a regional reference center for active surveillance of VL was established and it recorded a total of 284 cases through 1995, a mean of 31.5 cases/year and about four-fold more than previously reported. Of the 284 cases, 150 (53%) were children (≤ 14 years of age), and of the 134 adults, 39 (29%) were coinfected with human immunodeficiency virus (HIV). The commonest viscerotropic zymodeme of Leishmania infantum, MON 1, was identified in 40 (93%) of 43 HIV-negative and eight (57%) of 14 HIV-positive patients. A…

AdultMalemedicine.medical_specialtyAdolescentAllopurinolMeglumine antimoniateNotifiable diseaseAntiprotozoal AgentsHIV InfectionsCohort StudiesAge DistributionMeglumineRecurrenceAmphotericin BVirologyInternal medicineAmphotericin BEpidemiologyOrganometallic CompoundsmedicineAnimalsHumansLeishmania infantumSex DistributionChildSicilyleishmaniasisAgedMeglumine Antimoniatebiologybusiness.industryInfantLeishmaniasisMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryInfectious DiseasesVisceral leishmaniasisChild PreschoolLeishmaniasis VisceralAntimonialDrug Therapy CombinationFemaleParasitologyLeishmania infantumbusinessmedicine.drug
researchProduct